DGAP-News: CEVEC Pharmaceuticals GmbH: CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA(R) in gene therapy
CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA(R) in gene therapy
08.01.2021 / 12:00
CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA
(R) in gene therapy
(R) Technology for manufacturing of gene therapy products
ELEVECTA
Cologne, Germany, January 8, 2021
CEVEC Pharmaceuticals GmbH (CEVEC) today announced the signing of a license agreement with Biogen Inc. (Biogen; Nasdaq: BIIB) for the use of CEVEC s proprietary ELEVECTA
(R) Technology for the manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications.
Mycoplasma Testing Market May See a Big Move : Major Giants InvivoGen, PromoCell, Lonza Group
Edison, NJ (SBWIRE) 12/23/2020 Global Mycoplasma Testing Market Report from AMA Research highlights deep analysis on market characteristics, sizing, estimates and growth by segmentation, regional breakdowns & country along with competitive landscape, players market shares, and strategies that are key in the market. The exploration provides a 360° view and insights, highlighting major outcomes of the industry. These insights help the business decision-makers to formulate better business plans and make informed decisions to improved profitability. In addition, the study helps venture or private players in understanding the companies in more detail to make better informed decisions. According to AMA, the Global Mycoplasma Testing market is expected to see growth rate of 12.5% and may see market size of USD1.19 Billion by 2024.